Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats.

British Journal of Pharmacology, 01 Jan 1985, 84(1):121-129
PMID: 2579697 PMCID: PMC1987217

Free full text in Europe PMC

Abstract 

Treatment of rats with reserpine in order to disrupt vesicular amine storage reduces 5-hydroxytryptamine (5-HT) levels throughout brain by 90-95%. Despite the drastic reduction in brain 5-HT content by reserpine, the 5-HT releasing drug p-chloramphetamine (PCA) produces a behavioural syndrome in reserpine-treated rats which is not different from that observed in normal animals given PCA. Prior treatment of reserpinized rats with p-chlorophenylalanine (PCPA), the irreversible tryptophan hydroxylase inhibitor which inhibits the synthesis of new 5-HT, prevents the PCA-induced behavioural syndrome. The 5-HT receptor antagonist methergoline, blocks the PCA effect in reserpine-treated rats. Treatment of reserpinized rats with pargyline, a non-selective inhibitor of monoamine oxidase, in order to increase cerebral 5-HT levels, shifts the PCA dose-response curve for inducing the 5-HT behavioural syndrome to the left. The specific 5-HT uptake blocker, fluoxetine, protects normal and reserpine-treated rats from the 5-HT depleting effects of PCA but does not always prevent the PCA-induced 5-HT behavioural syndrome. These results indicate that PCA releases 5-HT into the synapse from a small cytoplasmic pool which is resistant to reserpine and suggest that this newly synthesized compartment of 5-HT represents the 'functional' transmitter pool.

Free full text 

Logo of brjpharmLink to Publisher's site
Br J Pharmacol. 1985 Jan; 84(1): 121–129.
PMCID: PMC1987217
PMID: 2579697

5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats.

D. M. Kuhn, W. A. Wolf, and M. B. Youdim
Copyright and License information Disclaimer

Abstract

Treatment of rats with reserpine in order to disrupt vesicular amine storage reduces 5-hydroxytryptamine (5-HT) levels throughout brain by 90-95%. Despite the drastic reduction in brain 5-HT content by reserpine, the 5-HT releasing drug p-chloramphetamine (PCA) produces a behavioural syndrome in reserpine-treated rats which is not different from that observed in normal animals given PCA. Prior treatment of reserpinized rats with p-chlorophenylalanine (PCPA), the irreversible tryptophan hydroxylase inhibitor which inhibits the synthesis of new 5-HT, prevents the PCA-induced behavioural syndrome. The 5-HT receptor antagonist methergoline, blocks the PCA effect in reserpine-treated rats. Treatment of reserpinized rats with pargyline, a non-selective inhibitor of monoamine oxidase, in order to increase cerebral 5-HT levels, shifts the PCA dose-response curve for inducing the 5-HT behavioural syndrome to the left. The specific 5-HT uptake blocker, fluoxetine, protects normal and reserpine-treated rats from the 5-HT depleting effects of PCA but does not always prevent the PCA-induced 5-HT behavioural syndrome. These results indicate that PCA releases 5-HT into the synapse from a small cytoplasmic pool which is resistant to reserpine and suggest that this newly synthesized compartment of 5-HT represents the 'functional' transmitter pool.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.4M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 121
121
icon of scanned page 122
122
icon of scanned page 123
123
icon of scanned page 124
124
icon of scanned page 125
125
icon of scanned page 126
126
icon of scanned page 127
127
icon of scanned page 128
128
icon of scanned page 129
129
 

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ashkenazi R, Finberg JP, Youdim MB. Behavioural hyperactivity in rats treated with selective monoamine oxidase inhibitors and LM 5008, a selective 5-hydroxytryptamine uptake blocker. Br J Pharmacol. 1983 Jul;79(3):765–770. [Europe PMC free article] [Abstract] [Google Scholar]
  • Bennett JP, Jr, Snyder SH. Serotonin and lysergic acid diethylamide binding in rat brain membranes: relationship to postsynaptic serotonin receptors. Mol Pharmacol. 1976 May;12(3):373–389. [Abstract] [Google Scholar]
  • Brown DR, Growdon JH. L-Tryptophan administration potentiates serotonin-dependent myoclonic behavior in the rat. Neuropharmacology. 1980 Apr;19(4):343–347. [Abstract] [Google Scholar]
  • Deakin JF, Green AR. The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol. 1978 Oct;64(2):201–209. [Europe PMC free article] [Abstract] [Google Scholar]
  • Dickinson SL, Jackson A, Curzon G. Effect of apomorphine on behaviour induced by 5-methoxy-N, N-dimethyl tryptamine: three different scoring methods give three different conclusions. Psychopharmacology (Berl) 1983;80(2):196–197. [Abstract] [Google Scholar]
  • Farnebo LO. Effect of d-amphetamine on spontaneous and stimulation-induced release of catecholamines. Acta Physiol Scand Suppl. 1971;371:45–52. [Abstract] [Google Scholar]
  • Fuller RW, Perry KW, Molloy BB. Effect of 3-(p-trifluoromethylphenoxy). N. N. methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine. J Pharmacol Exp Ther. 1975 Jun;193(3):793–803. [Abstract] [Google Scholar]
  • Fuxe K, Hökfelt T, Nilsson O, Reinius S. A fluorescence and electron microscopic study on central monoamine nerve cells. Anat Rec. 1966 May;155(1):33–40. [Abstract] [Google Scholar]
  • Green AR. Pharmacological studies on serotonin-mediated behaviour. J Physiol (Paris) 1981;77(2-3):437–447. [Abstract] [Google Scholar]
  • Green AR, Grahame-Smith DG. Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature. 1976 Apr 8;260(5551):487–491. [Abstract] [Google Scholar]
  • Green AR, Guy AP, Gardner CR. The behavioural effects of RU 24969, a suggested 5-HT1 receptor agonist in rodents and the effect on the behaviour of treatment with antidepressants. Neuropharmacology. 1984 Jun;23(6):655–661. [Abstract] [Google Scholar]
  • Green AR, Youdim MB. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol. 1975 Nov;55(3):415–422. [Europe PMC free article] [Abstract] [Google Scholar]
  • Halaris AE, Freedman DX. Loss of body weight as a predictor of reserpine-induced amine depletion. Eur J Pharmacol. 1975 May;32(1):93–101. [Abstract] [Google Scholar]
  • Jacobs BL. An animal behavior model for studying central serotonergic synapses. Life Sci. 1976 Sep 15;19(6):777–785. [Abstract] [Google Scholar]
  • Jéquier E, Lovenberg W, Sjoerdsma A. Tryptophan hydroxylase inhibition: the mechanism by which p-chlorophenylalanine depletes rat brain serotonin. Mol Pharmacol. 1967 May;3(3):274–278. [Abstract] [Google Scholar]
  • Joh TH, Shikimi T, Pickel VM, Reis DJ. Brain tryptophan hydroxylase: purification of, production of antibodies to, and cellular and ultrastructural localization in serotonergic neurons of rat midbrain. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3575–3579. [Europe PMC free article] [Abstract] [Google Scholar]
  • Koe BK, Weissman A. p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther. 1966 Dec;154(3):499–516. [Abstract] [Google Scholar]
  • Lane JD, Aprison MH. The flux of radioactive label through components of the serotonergic system following the injection of [3H]tryptophan: product--precursor anomalies providing evidence that serotonin exists in multiple pools. J Neurochem. 1978 Apr;30(4):671–678. [Abstract] [Google Scholar]
  • Long JB, Youngblood WY, Kizer JS. Regional differences in the response of serotonergic neurons in rat CNS to drugs. Eur J Pharmacol. 1983 Mar 18;88(1):89–97. [Abstract] [Google Scholar]
  • Morot-Gaudry Y, Bourgoin S, Hamon M. Kinetic characteristics of newly synthesized 3H-5-HT in the brain of control and reserpinized mice. Evidence for the heterogeneous distribution of 5-HT in serotoninergic neurons. Naunyn Schmiedebergs Arch Pharmacol. 1981 Jul;316(4):311–316. [Abstract] [Google Scholar]
  • Ogren SO, Ross SB. Substituted amphetamine derivatives. II. Behavioural effects in mice related to monoaminergic neurones. Acta Pharmacol Toxicol (Copenh) 1977 Oct;41(4):353–368. [Abstract] [Google Scholar]
  • Ortmann R, Waldmeier PC, Radeke E, Felner A, Delini-Stula A. The effects of 5-HT uptake- and MAO-inhibitors on L-5-HTP-induced excitation in rats. Naunyn Schmiedebergs Arch Pharmacol. 1980 Mar;311(2):185–192. [Abstract] [Google Scholar]
  • Randrup A, Munkvad I. Role of catecholamines in the amphetamine excitatory response. Nature. 1966 Jul 30;211(5048):540–540. [Abstract] [Google Scholar]
  • Ross SB, Kelder D. Efflux of 5-hydroxytryptamine from synaptosomes of rat cerebral cortex. Acta Physiol Scand. 1977 Jan;99(1):27–36. [Abstract] [Google Scholar]
  • Sanders-Bush E, Bushing JA, Sulser F. p-Chloroamphetamine--inhibition of cerebral tryptophan hydroxylase. Biochem Pharmacol. 1972 May 15;21(10):1501–1510. [Abstract] [Google Scholar]
  • Sanders-Bush E, Massari VJ. Actions of drugs that deplete serotonin. Fed Proc. 1977 Jul;36(8):2149–2153. [Abstract] [Google Scholar]
  • Shields PJ, Eccleston D. Evidence for the synthesis and storage of 5-hydroxytryptamine in two separate pools in the brain. J Neurochem. 1973 Mar;20(3):881–888. [Abstract] [Google Scholar]
  • Sloviter RS, Drust EG, Connor JD. Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Ther. 1978 Aug;206(2):339–347. [Abstract] [Google Scholar]
  • Svensson TH. The effect of inhibition of catecholamine synthesis on dexamphetamine induced central stimulation. Eur J Pharmacol. 1970 Oct;12(2):161–166. [Abstract] [Google Scholar]
  • Tissari AH, Raunu EM. Subcellular distribution of 5-hydroxytryptamine in rat brain during development: effect of drugs and fasting. J Neurochem. 1975 Jun;24(6):1143–1150. [Abstract] [Google Scholar]
  • Tracqui P, Morot-Gaudry Y, Staub JF, Brézillon P, Perault-Staub AM, Bourgoin S, Hamon M. Model of brain serotonin metabolism. II. Physiological interpretation. Am J Physiol. 1983 Feb;244(2):R206–R215. [Abstract] [Google Scholar]
  • Trulson ME, Jacobs BL. Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine. Eur J Pharmacol. 1976 Mar;36(1):149–154. [Abstract] [Google Scholar]
  • Weissman A, Koe BK, Tenen SS. Antiamphetamine effects following inhibition of tyrosine hydroxylase. J Pharmacol Exp Ther. 1966 Mar;151(3):339–352. [Abstract] [Google Scholar]
  • Wolf WA, Kuhn DM. Simultaneous determination of 5-hydroxytryptamine, its amino acid precursors and acid metabolite in discrete brain regions by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1983 Jun 10;275(1):1–9. [Abstract] [Google Scholar]
Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

Citations & impact 

Impact metrics

52
Citations
Jump to Citations

Citations of article over time

Article citations

Go to all (52) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.